The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.

MLA

Armuzzi, Alessandro, et al. “The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.” Inflammatory Bowel Diseases, vol. 25, no. 1/3/1900, Mar. 2019, pp. 568–79. EBSCOhost, https://doi.org/10.1093/ibd/izy264.

APA

Armuzzi, A., Fiorino, G., Variola, A., Manetti, N., Fries, W., Orlando, A., Maconi, G., Bossa, F., Cappello, M., Biancone, L., Cantoro, L., Costa, F., D’Incà, R., Lionetti, P., Principi, M., Castiglione, F., Annunziata, M. L., Sabatino, A. D., Girolamo, M. D., & Terpin, M. M. (2019). The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases, 25(1/3/1900), 568–579. https://doi.org/10.1093/ibd/izy264

Chicago

Armuzzi, Alessandro, Gionata Fiorino, Angela Variola, Natalia Manetti, Walter Fries, Ambrogio Orlando, Giovanni Maconi, et al. 2019. “The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.” Inflammatory Bowel Diseases 25 (1/3/1900): 568–79. doi:10.1093/ibd/izy264.